Targeting CCL21-folic acid-upconversion nanoparticles conjugates to folate receptor-α expressing tumor cells in an endothelial-tumor cell bilayer model

Biomaterials

Volumn 34, Issue 20, 2013, Pages 4860-4871

  Lee, Kim Yee ^a   Seow, Eileen ^a   Zhang, Yong ^a,b   Lim, Yaw Chyn ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chemokine; Endothelial tumor cell bilayer; Folate conjugate; T cell migration; Upconversion nanoparticles

Indexed keywords

BI-LAYER; CHEMOKINES; FLUORESCENT NANOPARTICLES; FOLATE-CONJUGATE; HOST IMMUNE RESPONSE; IMMUNOSURVEILLANCE; OVARIAN CARCINOMA CELL; UPCONVERSION NANOPARTICLES;

BIOCOMPATIBILITY; CELL CULTURE; CYTOTOXICITY; IMMUNE SYSTEM; MONOLAYERS; NANOCONJUGATES; NANOPARTICLES; ORGANIC ACIDS; T-CELLS; TUMORS;

ENDOTHELIAL CELLS;

FOLATE RECEPTOR 1; FOLIC ACID; NANOCOATING; NANOPARTICLE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SILICON DIOXIDE;

ARTICLE; BILAYER MEMBRANE; BINDING AFFINITY; BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONJUGATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTERNALIZATION; MONOLAYER CULTURE; NEUTROPHIL CHEMOTAXIS; OVARY ADENOCARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; ZETA POTENTIAL;

CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL21; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; POROSITY; SILICON DIOXIDE; SPECTROMETRY, FLUORESCENCE;

EID: 84876087412     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.029     Document Type: Article

References (40)

1. Stewart T.J., Abrams S.I. How tumours escape mass destruction. Oncogene 2008, 27:5894-5903.
2. Stewart T., Smyth M. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011, 30:125-140.
3. Homey B., Muller A., Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol 2002, 2:175-184.
4. Lechner M.G., Russell S.M., Bass R.S., Epstein A.L. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy 2011, 3:1317-1340.
5. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
6. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
7. Johnson L.A., Jackson D.G. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int Immunol 2010, 22:839-849.
8. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
9. Okada T., Miller M.J., Parker I., Krummel M.F., Neighbors M., Hartley S.B., et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005, 3:e150.
10. Robertson M.J. Role of chemokines in the biology of natural killer cells. JLeukoc Biol 2002, 71:173-183.
11. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses invivo. JImmunol (Baltimore, Md: 1950) 2000, 164:4558-4563.
12. Kar U.K., Srivastava M.K., Andersson Å., Baratelli F., Huang M., Kickhoefer V.A., et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE 2011, 6:e18758.
13. Brzezinska A., Winska P., Balinska M. Cellular aspects of folate and antifolate membrane transport. Acta Biochim Pol 2000, 47:735-749.
14. Matherly L.H., Goldman I.D. Membrane transport of folates. Vitam Horm 2003, 403-456.
15. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999, 19:91-122.
16. Antony A. The biological chemistry of folate receptors. Blood 1992, 79:2807-2820.
17. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-1084.
18. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues invivo and in established cell lines. Physiologic and clinical implications. Cancer 1994, 73:2432-2443.
19. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993, 142:557-567.
20. Lee R.J., Low P.S. Folate as a targeting device for proteins utilizing folate receptor-mediated endocytosis. Methods Mol Med 2000, 25:69-76.
21. Bünzli J.-C.G. Lanthanide luminescence for biomedical analyses and imaging. Chem Rev 2010, 110:2729-2755.
22. Bouzigues C., Gacoin T., Alexandrou A. Biological applications of rare-earth based nanoparticles. ACS Nano 2011, 5:8488-8505.
23. Li Z., Zhang Y. An efficient and user-friendly method for the synthesis of hexagonal-phase NaYF 4:Yb, Er/Tm nanocrystals with controllable shape and upconversion fluorescence. Nanotechnology 2008, 19:345606.
24. Qian H.S., Guo H.C., Ho P.C., Mahendran R., Zhang Y. Mesoporous-silica-coated up-conversion fluorescent nanoparticles for photodynamic therapy. Small (Weinheim an der Bergstrasse, Germany) 2009, 5:2285-2290.
25. Idris N.M., Gnanasammandhan M.K., Zhang J., Ho P.C., Mahendran R., Zhang Y. Invivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med 2012, 18:1580-1585.
26. Zhang M., Wu Y., Feng X., He X., Chen L., Zhang Y. Fabrication of mesoporous silica-coated CNTs and application in size-selective protein separation. JMater Chem 2010, 20:5835-5842.
27. Wang F., Banerjee D., Liu Y., Chen X., Liu X. Upconversion nanoparticles in biological labeling, imaging, and therapy. Analyst 2010, 135:1839-1854.
28. Li C., Liu J., Alonso S., Li F., Zhang Y. Upconversion nanoparticles for sensitive and in-depth detection of Cu2+ ions. Nanoscale 2012, 4:6065-6071.
29. Shenoy D.B., Amiji M.M. Poly(ethylene oxide)-modified poly(e-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005, 293:261-270.
30. Mahapatro A., Singh D. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. JNanobiotechnol 2011, 9:55.
31. Smart E.J., Mineo C., Anderson R.G. Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of MA104 cells. JCell Biol 1996, 134:1169-1177.
32. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13:256-262.
33. Lin S.-Y., Lee W.-R., Su Y.-F., Hsu S.-P., Lin H.-C., Ho P.-Y., et al. Folic acid inhibitsendothelial cell proliferation through activating the cSrc/ERK 2/NF-κB/p53 pathway mediated by folic acid receptor. Angiogenesis 2012, 15:671-683.
34. Blom H.J. Folic acid, methylation and neural tube closure in humans. Birth Defects Res Part A Clin Mol Teratol 2009, 85:295-302.
35. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry 1995, 34:5660-5665.
36. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006, 8:1223-1234.
37. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11:812-818.
38. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
39. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
40. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.